"Immunocompromised Host" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
| Descriptor ID |
D016867
|
| MeSH Number(s) |
G12.470
|
| Concept/Terms |
Immunocompromised Host- Immunocompromised Host
- Host, Immunocompromised
- Hosts, Immunocompromised
- Immunocompromised Hosts
- Immunocompromised Patient
- Immunocompromised Patients
- Patient, Immunocompromised
- Patients, Immunocompromised
- Immunosuppressed Host
- Host, Immunosuppressed
- Hosts, Immunosuppressed
- Immunosuppressed Hosts
|
Below are MeSH descriptors whose meaning is more general than "Immunocompromised Host".
Below are MeSH descriptors whose meaning is more specific than "Immunocompromised Host".
This graph shows the total number of publications written about "Immunocompromised Host" by people in this website by year, and whether "Immunocompromised Host" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunocompromised Host" by people in Profiles.
-
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
-
SARS-CoV-2 Clinical Outcomes in Patients with Cancer in a Large Integrated Health Care System in Northern California. Oncologist. 2021 03; 26(3):e500-e504.
-
Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
-
In Reply II-Risk of Disseminated Disease in Immunocompromised Patients Receiving Live Zoster Vaccine. Mayo Clin Proc. 2016 07; 91(7):971-2.
-
The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated With Persistent Infections and Adverse Outcomes Independent From Its Multidrug Resistance and Associations With Compromised Hosts. Clin Infect Dis. 2016 06 15; 62(12):1529-1536.
-
Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis. 2014 Oct; 59(7):913-9.
-
Medical conditions with neuropsychiatric manifestations. Med Clin North Am. 2014 Sep; 98(5):1193-208.
-
Complications of herpes zoster in cancer patients. Scand J Infect Dis. 2014 Jul; 46(7):528-32.
-
Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. J Infect Dis. 2013 Dec 01; 208(11):1859-68.
-
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014 Nov; 73(11):1942-8.